Connect Biopharma Holdings Limited
CNTB
$2.55
$0.010.39%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/22/2026
-
MarketBeat
8/13/2026
-
Seeking Alpha - Healthcare
8/13/2026
-
TipRanks
Connect Biopharma (NASDAQ:CNTB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS
8/12/2026
-
MarketBeat
8/12/2026
-
Globe Newswire
8/8/2026
-
The Cerbat Gem
8/8/2026
-
MarketBeat
8/5/2026
-
MarketBeat
7/19/2026
-
The Cerbat Gem
7/15/2026
-
TipRanks
7/9/2026
-
TipRanks
7/9/2026
-
MarketBeat
6/30/2026
-
TipRanks
6/25/2026
-
The Cerbat Gem
6/18/2026
-
TipRanks
6/17/2026
-
TipRanks
6/17/2026
-
Globe Newswire
5/30/2026
-
The Cerbat Gem
5/26/2026
-
TipRanks Financial Blog
5/22/2026
-
MarketBeat
5/22/2026
-
The Cerbat Gem
5/20/2026
-
Simply Wall St
5/14/2026
-
The Cerbat Gem
5/12/2026
-
Globe Newswire
5/12/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, August 12, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 9 and 13 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
877 245 2787
Address
3580 Carmel Mountain Road
Suite 200
San Diego, CA 92130
Suite 200
San Diego, CA 92130
Country
Year Founded
Business Description
Sector
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra...
more